Mechanism of fenestrae assembly in mammalian endothelial cells

哺乳动物内皮细胞窗孔组装机制

基本信息

  • 批准号:
    9166840
  • 负责人:
  • 金额:
    $ 32.4万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-09-01 至 2020-05-31
  • 项目状态:
    已结题

项目摘要

FENESTRAE are circular transcellular pores in vascular endothelial cells playing critical roles in the maintenance of normal endothelial barrier function, blood homeostasis and ultimately survival. Fenestrae are spanned in most cases by a protein barrier called a fenestral diaphragm (FD). There is a significant knowledge gap in our understanding of the basic cell biological mechanism of fenestrae assembly, which is the subject of this proposal. Recently, our group demonstrated that Plasmalemma Vesicle Associated Protein (PLVAP or PV1) is critical for FD assembly, and that absence of PV1 in mice and humans causes abnormal fenestrae and early postnatal lethality due to multiple vascular defects. Critically for this proposal, PV1 is the only known marker for fenestrae, and we will exploit this property in our investigation of fenestrae assembly mechanisms. Our central hypothesis is that fenestrae assembly follows a three-step model: In Step 1, controlled actin depolymerization leads to cell thinning and apposition of apical and basal plasma membranes to within 50 nm. In Step 2, fenestrae pores form by fusion of exocytic vesicles with apical and basal membranes. In Step 3, the FD assembles using exocytosed PV1 and its interacting partners. This hypothesis is based on our key new observations including: 1) Arp2/3 complex inhibition induces fenestrae assembly; 2) de novo formation of the FD requires exocytosis of PV1 from an internal pool; 3) fenestrae assembly does not require caveolin 1, caveolae or PV1 endocytosis. We will critically test specific aspects of this model, using a functionally validated endothelial cell culture system. In Aim 1 we will define the role and mechanism of actin depolymerization in fenestrae formation. Using our fenestrae morphogenesis assay, we will determine the spatio-temporal relationship between actin disassembly and cell thinning, and will elucidate the roles of actin nucleators and actin depolymerizers. In Aim 2 we will define the mechanism of fenestrae pore formation. We will use live-cell microscopy to measure the timing of PV1 delivery to the cell surface, and identify the intracellular compartment(s) from which exocytosed PV1 is derived. In Aim 3 we will define the determinants of fenestrae diaphragm assembly. We hypothesize that PV1 is the major FD structural component, but requires additional proteins for functional FD assembly. We will use a combination of biochemistry and cellular complementation to test PV1 oligomerization structurally and functionally, and will test five PV1 interacting proteins we recently identified for roles in FD assembly. We are uniquely positioned both in terms of key and necessary expertise to complete this work. These investigations will define the assembly mechanism for an intricate and physiologically relevant cellular structure, providing valuable cell biological insight that is currently lacking.
窗孔是血管内皮细胞中的圆形跨细胞孔,在血管内皮细胞的增殖和分化中起关键作用。 维持正常内皮屏障功能、血液稳态和最终存活。窗孔是 在大多数情况下,由称为窗隔(FD)的蛋白质屏障跨越。有一个重要的知识 我们对窗孔组装的基本细胞生物学机制的理解存在差距,这是 这个提议。最近,我们的小组证明质膜囊泡相关蛋白(PLVAP或 PV 1)对于FD组装是关键的,并且在小鼠和人类中PV 1的缺乏导致异常的窗孔, 由于多处血管缺陷导致的出生后早期死亡。对于该提案至关重要的是,PV 1是唯一已知的 标记的窗,我们将利用这个属性在我们的调查窗组装机制。 我们的中心假设是,窗孔组装遵循三步模型:在第一步,控制肌动蛋白 解聚导致细胞变薄和顶端和基底质膜的并置在50 nm以内。 在步骤2中,通过胞吐囊泡与顶膜和基膜融合形成窗孔。在步骤3中, FD使用胞吐的PV 1及其相互作用伴侣组装。这一假设是基于我们的关键新的 观察结果包括:1)Arp 2/3复合物抑制诱导窗孔组装; 2)新形成的 FD需要从内部池胞吐PV 1; 3)窗孔组装不需要小窝蛋白1, 小窝或PV 1内吞作用。我们将严格测试该模型的特定方面,使用功能验证的 内皮细胞培养系统。在目标1中,我们将定义肌动蛋白解聚在 窗孔形成使用我们的窗孔形态发生试验,我们将确定时空 肌动蛋白分解和细胞变薄之间的关系,并将阐明肌动蛋白成核剂和 肌动蛋白解聚剂。在目标2中,我们将定义窗孔形成的机制。我们将使用活细胞 显微镜下测量PV 1递送到细胞表面的时间,并鉴定细胞内的 细胞外切的PV 1来源于的隔室。在目标3中,我们将定义窗的决定因素 隔膜组件我们假设PV 1是FD的主要结构成分,但需要额外的 用于功能性FD组装的蛋白质。我们将结合生物化学和细胞互补 测试PV 1寡聚化的结构和功能,并将测试五个PV 1相互作用蛋白,我们最近 在FD装配中的角色。我们在关键和必要的专业知识方面都处于独特的地位, 完成这项工作。这些调查将确定一个复杂的组装机制, 生理相关的细胞结构,提供了目前缺乏的有价值的细胞生物学见解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RADU VIRGIL STAN其他文献

RADU VIRGIL STAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RADU VIRGIL STAN', 18)}}的其他基金

Novel regulators, components and function of endothelial diaphragms
内皮隔膜的新型调节器、组件和功能
  • 批准号:
    10339380
  • 财政年份:
    2021
  • 资助金额:
    $ 32.4万
  • 项目类别:
Novel regulators, components and function of endothelial diaphragms
内皮隔膜的新型调节器、组件和功能
  • 批准号:
    10560620
  • 财政年份:
    2021
  • 资助金额:
    $ 32.4万
  • 项目类别:
Olympus TIRF Microscope for Simultaneous Multichannel Live cell Imaging
用于同时多通道活细胞成像的奥林巴斯 TIRF 显微镜
  • 批准号:
    8447267
  • 财政年份:
    2013
  • 资助金额:
    $ 32.4万
  • 项目类别:
Plasmalemma vesicle-associated protein (PV-1) as a novel target in cancer immunot
质膜囊泡相关蛋白(PV-1)作为癌症免疫的新靶点
  • 批准号:
    8491338
  • 财政年份:
    2013
  • 资助金额:
    $ 32.4万
  • 项目类别:
Plasmalemma vesicle-associated protein (PV-1) as a novel target in cancer immunot
质膜囊泡相关蛋白(PV-1)作为癌症免疫的新靶点
  • 批准号:
    8645617
  • 财政年份:
    2013
  • 资助金额:
    $ 32.4万
  • 项目类别:
Structure and Function of Endothelial Fenestrae
内皮窗孔的结构和功能
  • 批准号:
    7929520
  • 财政年份:
    2009
  • 资助金额:
    $ 32.4万
  • 项目类别:
Structure and Function of Endothelial Fenestrae
内皮窗孔的结构和功能
  • 批准号:
    7730256
  • 财政年份:
    2009
  • 资助金额:
    $ 32.4万
  • 项目类别:
Cellular and Molecular Mechanisms of Vascular Permeability
血管通透性的细胞和分子机制
  • 批准号:
    7342057
  • 财政年份:
    2006
  • 资助金额:
    $ 32.4万
  • 项目类别:
Cellular and Molecular Mechanisms of Vascular Permeability
血管通透性的细胞和分子机制
  • 批准号:
    7576089
  • 财政年份:
    2006
  • 资助金额:
    $ 32.4万
  • 项目类别:
Cellular/Molecular Mechanisms of Vascular Permeability
血管通透性的细胞/分子机制
  • 批准号:
    7022442
  • 财政年份:
    2006
  • 资助金额:
    $ 32.4万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 32.4万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.4万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 32.4万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.4万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 32.4万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.4万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 32.4万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 32.4万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 32.4万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.4万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了